Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-01-06

AUTHORS

Andreas Flores Martin, Priya Shanmugarajah, Nigel Hoggard, Marios Hadjivassiliou

ABSTRACT

Superficial siderosis describes haemosiderin deposition on the surface of the brain. When present on infratentorial structures, it can cause ataxia, sensorineural hearing loss and pyramidal signs. There is no proven treatment and patients experience slow progression of symptoms. Iron-chelating agents have been suggested as a therapeutic option and deferiprone is suited as it crosses the blood-brain barrier. However, deferiprone is reported to have a 1–2% risk of agranulocytosis. We performed a systematic review on treatment of infratentorial superficial siderosis with deferiprone based on PRISMA guidelines. Studies were included if in English or an English language translation was available, were about human subjects and referred to patients with ataxia. Studies were excluded if they did not possess an English translation, included animal studies or did not have ataxia. Studies were excluded if they discussed cerebral amyloid angiopathy or siderosis of other regions. Eleven papers were included. We identified 69 patients. Seventeen patients (25%) discontinued the drug. The most encountered adverse effect was anaemia (21.7%). Neutropaenia was observed in 8.7% and agranulocytosis in 5.8% of patients. Clinically, response varied, and stability or improvement was seen across neurological domains in 6 studies while 5 showed a mixed response. On imaging, 13 (28.9%) patients improved, 24 (53.3%) stabilised and 8 (17.8%) deteriorated. A prospective international centralised register of patients should be developed to inform the design and conduct of a multicentre, placebo-controlled, randomised clinical trial to evaluate the efficacy of deferiprone. The evidence from this systematic review is that deferiprone is a promising intervention. More... »

PAGES

454-461

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12311-020-01222-7

DOI

http://dx.doi.org/10.1007/s12311-020-01222-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1134387398

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33409768


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deferiprone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemosiderin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Chelating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Siderosis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Flores Martin", 
        "givenName": "Andreas", 
        "id": "sg:person.011004675327.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011004675327.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shanmugarajah", 
        "givenName": "Priya", 
        "id": "sg:person.01273701327.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273701327.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoggard", 
        "givenName": "Nigel", 
        "id": "sg:person.0610025364.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610025364.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hadjivassiliou", 
        "givenName": "Marios", 
        "id": "sg:person.01354423242.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354423242.83"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ncpneuro0356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030282682", 
          "https://doi.org/10.1038/ncpneuro0356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-014-1709-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017883418", 
          "https://doi.org/10.1007/s10072-014-1709-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-019-03791-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112519703", 
          "https://doi.org/10.1007/s10072-019-03791-w"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-019-03847-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112941757", 
          "https://doi.org/10.1007/s10072-019-03847-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-019-09577-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1121856716", 
          "https://doi.org/10.1007/s00415-019-09577-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686141", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011802558", 
          "https://doi.org/10.1007/bf00686141"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41582-018-0020-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104991494", 
          "https://doi.org/10.1038/s41582-018-0020-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-01-06", 
    "datePublishedReg": "2021-01-06", 
    "description": "Superficial siderosis describes haemosiderin deposition on the surface of the brain. When present on infratentorial structures, it can cause ataxia, sensorineural hearing loss and pyramidal signs. There is no proven treatment and patients experience slow progression of symptoms. Iron-chelating agents have been suggested as a therapeutic option and deferiprone is suited as it crosses the blood-brain barrier. However, deferiprone is reported to have a 1\u20132% risk of agranulocytosis. We performed a systematic review on treatment of infratentorial superficial siderosis with deferiprone based on PRISMA guidelines. Studies were included if in English or an English language translation was available, were about human subjects and referred to patients with ataxia. Studies were excluded if they did not possess an English translation, included animal studies or did not have ataxia. Studies were excluded if they discussed cerebral amyloid angiopathy or siderosis of other regions. Eleven papers were included. We identified 69 patients. Seventeen patients (25%) discontinued the drug. The most encountered adverse effect was anaemia (21.7%). Neutropaenia was observed in 8.7% and agranulocytosis in 5.8% of patients. Clinically, response varied, and stability or improvement was seen across neurological domains in 6 studies while 5 showed a mixed response. On imaging, 13 (28.9%) patients improved, 24 (53.3%) stabilised and 8 (17.8%) deteriorated. A prospective international centralised register of patients should be developed to inform the design and conduct of a multicentre, placebo-controlled, randomised clinical trial to evaluate the efficacy of deferiprone. The evidence from this systematic review is that deferiprone is a promising intervention.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12311-020-01222-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028483", 
        "issn": [
          "1473-4222", 
          "1473-4230"
        ], 
        "name": "The Cerebellum", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "infratentorial superficial siderosis", 
      "superficial siderosis", 
      "systematic review", 
      "efficacy of deferiprone", 
      "risk of agranulocytosis", 
      "blood-brain barrier", 
      "register of patients", 
      "sensorineural hearing loss", 
      "haemosiderin deposition", 
      "therapeutic options", 
      "iron-chelating agent", 
      "infratentorial structures", 
      "pyramidal signs", 
      "clinical trials", 
      "slow progression", 
      "treatment response", 
      "hearing loss", 
      "PRISMA guidelines", 
      "patients", 
      "animal studies", 
      "siderosis", 
      "neurological domains", 
      "promising intervention", 
      "deferiprone", 
      "adverse effects", 
      "ataxia", 
      "agranulocytosis", 
      "human subjects", 
      "mixed response", 
      "treatment", 
      "review", 
      "multicentre", 
      "neutropaenia", 
      "response", 
      "anemia", 
      "symptoms", 
      "study", 
      "brain", 
      "progression", 
      "trials", 
      "drugs", 
      "efficacy", 
      "intervention", 
      "risk", 
      "signs", 
      "Register", 
      "subjects", 
      "guidelines", 
      "options", 
      "agents", 
      "evidence", 
      "loss", 
      "effect", 
      "improvement", 
      "barriers", 
      "translation", 
      "International", 
      "conduct", 
      "English", 
      "region", 
      "English language translation", 
      "deposition", 
      "domain", 
      "design", 
      "language translation", 
      "surface", 
      "stability", 
      "structure", 
      "English translation", 
      "paper"
    ], 
    "name": "Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review", 
    "pagination": "454-461", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1134387398"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12311-020-01222-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33409768"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12311-020-01222-7", 
      "https://app.dimensions.ai/details/publication/pub.1134387398"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_908.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12311-020-01222-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01222-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01222-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01222-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01222-7'


 

This table displays all metadata directly associated to this object as RDF triples.

210 TRIPLES      21 PREDICATES      109 URIs      94 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12311-020-01222-7 schema:about N07be92d9bf1748c189727b71dfbbae5c
2 N0cd254efad8c44389d5ed5a6a881a867
3 N4841e65939bc433ea99098b40b15dfef
4 N9d978dc0b4234903ba812c24bc3bab1f
5 Nb7ea306e43f648d292ce5168f4188270
6 Nf282ffbd33634f2a9813f754c3b49209
7 Nfa8c3a8731a04f04bb6e09587d28acfe
8 anzsrc-for:11
9 anzsrc-for:1103
10 schema:author Nc3ede21df73649949014a5f045fcd6d5
11 schema:citation sg:pub.10.1007/bf00686141
12 sg:pub.10.1007/s00415-019-09577-6
13 sg:pub.10.1007/s10072-014-1709-5
14 sg:pub.10.1007/s10072-019-03791-w
15 sg:pub.10.1007/s10072-019-03847-x
16 sg:pub.10.1038/ncpneuro0356
17 sg:pub.10.1038/s41582-018-0020-0
18 schema:datePublished 2021-01-06
19 schema:datePublishedReg 2021-01-06
20 schema:description Superficial siderosis describes haemosiderin deposition on the surface of the brain. When present on infratentorial structures, it can cause ataxia, sensorineural hearing loss and pyramidal signs. There is no proven treatment and patients experience slow progression of symptoms. Iron-chelating agents have been suggested as a therapeutic option and deferiprone is suited as it crosses the blood-brain barrier. However, deferiprone is reported to have a 1–2% risk of agranulocytosis. We performed a systematic review on treatment of infratentorial superficial siderosis with deferiprone based on PRISMA guidelines. Studies were included if in English or an English language translation was available, were about human subjects and referred to patients with ataxia. Studies were excluded if they did not possess an English translation, included animal studies or did not have ataxia. Studies were excluded if they discussed cerebral amyloid angiopathy or siderosis of other regions. Eleven papers were included. We identified 69 patients. Seventeen patients (25%) discontinued the drug. The most encountered adverse effect was anaemia (21.7%). Neutropaenia was observed in 8.7% and agranulocytosis in 5.8% of patients. Clinically, response varied, and stability or improvement was seen across neurological domains in 6 studies while 5 showed a mixed response. On imaging, 13 (28.9%) patients improved, 24 (53.3%) stabilised and 8 (17.8%) deteriorated. A prospective international centralised register of patients should be developed to inform the design and conduct of a multicentre, placebo-controlled, randomised clinical trial to evaluate the efficacy of deferiprone. The evidence from this systematic review is that deferiprone is a promising intervention.
21 schema:genre article
22 schema:isAccessibleForFree true
23 schema:isPartOf N451f180360914ab0aa0cc46a3846922f
24 Nb5b8e0d3466a47df864bc075ed91bd3f
25 sg:journal.1028483
26 schema:keywords English
27 English language translation
28 English translation
29 International
30 PRISMA guidelines
31 Register
32 adverse effects
33 agents
34 agranulocytosis
35 anemia
36 animal studies
37 ataxia
38 barriers
39 blood-brain barrier
40 brain
41 clinical trials
42 conduct
43 deferiprone
44 deposition
45 design
46 domain
47 drugs
48 effect
49 efficacy
50 efficacy of deferiprone
51 evidence
52 guidelines
53 haemosiderin deposition
54 hearing loss
55 human subjects
56 improvement
57 infratentorial structures
58 infratentorial superficial siderosis
59 intervention
60 iron-chelating agent
61 language translation
62 loss
63 mixed response
64 multicentre
65 neurological domains
66 neutropaenia
67 options
68 paper
69 patients
70 progression
71 promising intervention
72 pyramidal signs
73 region
74 register of patients
75 response
76 review
77 risk
78 risk of agranulocytosis
79 sensorineural hearing loss
80 siderosis
81 signs
82 slow progression
83 stability
84 structure
85 study
86 subjects
87 superficial siderosis
88 surface
89 symptoms
90 systematic review
91 therapeutic options
92 translation
93 treatment
94 treatment response
95 trials
96 schema:name Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review
97 schema:pagination 454-461
98 schema:productId N094511c3480845da939bb58c97201e70
99 N2bee6da07fca4630ad0c413ee33003f6
100 N38053748886f4c4fbf6139fbe3bb36c0
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134387398
102 https://doi.org/10.1007/s12311-020-01222-7
103 schema:sdDatePublished 2022-12-01T06:42
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N8695f093a4bb4c1e8fe056c0d5c65228
106 schema:url https://doi.org/10.1007/s12311-020-01222-7
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N07be92d9bf1748c189727b71dfbbae5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Hemosiderin
112 rdf:type schema:DefinedTerm
113 N094511c3480845da939bb58c97201e70 schema:name doi
114 schema:value 10.1007/s12311-020-01222-7
115 rdf:type schema:PropertyValue
116 N0cd254efad8c44389d5ed5a6a881a867 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Iron Chelating Agents
118 rdf:type schema:DefinedTerm
119 N2bee6da07fca4630ad0c413ee33003f6 schema:name dimensions_id
120 schema:value pub.1134387398
121 rdf:type schema:PropertyValue
122 N38053748886f4c4fbf6139fbe3bb36c0 schema:name pubmed_id
123 schema:value 33409768
124 rdf:type schema:PropertyValue
125 N451f180360914ab0aa0cc46a3846922f schema:volumeNumber 20
126 rdf:type schema:PublicationVolume
127 N4841e65939bc433ea99098b40b15dfef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Animals
129 rdf:type schema:DefinedTerm
130 N62de6ce338224929948a78da1c7500a9 rdf:first sg:person.0610025364.39
131 rdf:rest Nbd141746a61e4235aeec2023ad00cfb8
132 N85557f82bce2474aa5a8c6ce0e157e82 rdf:first sg:person.01273701327.13
133 rdf:rest N62de6ce338224929948a78da1c7500a9
134 N8695f093a4bb4c1e8fe056c0d5c65228 schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N9d978dc0b4234903ba812c24bc3bab1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 Nb5b8e0d3466a47df864bc075ed91bd3f schema:issueNumber 3
140 rdf:type schema:PublicationIssue
141 Nb7ea306e43f648d292ce5168f4188270 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Deferiprone
143 rdf:type schema:DefinedTerm
144 Nbd141746a61e4235aeec2023ad00cfb8 rdf:first sg:person.01354423242.83
145 rdf:rest rdf:nil
146 Nc3ede21df73649949014a5f045fcd6d5 rdf:first sg:person.011004675327.88
147 rdf:rest N85557f82bce2474aa5a8c6ce0e157e82
148 Nf282ffbd33634f2a9813f754c3b49209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Siderosis
150 rdf:type schema:DefinedTerm
151 Nfa8c3a8731a04f04bb6e09587d28acfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Randomized Controlled Trials as Topic
153 rdf:type schema:DefinedTerm
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
158 schema:name Clinical Sciences
159 rdf:type schema:DefinedTerm
160 sg:journal.1028483 schema:issn 1473-4222
161 1473-4230
162 schema:name The Cerebellum
163 schema:publisher Springer Nature
164 rdf:type schema:Periodical
165 sg:person.011004675327.88 schema:affiliation grid-institutes:grid.11835.3e
166 schema:familyName Flores Martin
167 schema:givenName Andreas
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011004675327.88
169 rdf:type schema:Person
170 sg:person.01273701327.13 schema:affiliation grid-institutes:grid.11835.3e
171 schema:familyName Shanmugarajah
172 schema:givenName Priya
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273701327.13
174 rdf:type schema:Person
175 sg:person.01354423242.83 schema:affiliation grid-institutes:grid.11835.3e
176 schema:familyName Hadjivassiliou
177 schema:givenName Marios
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354423242.83
179 rdf:type schema:Person
180 sg:person.0610025364.39 schema:affiliation grid-institutes:grid.11835.3e
181 schema:familyName Hoggard
182 schema:givenName Nigel
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610025364.39
184 rdf:type schema:Person
185 sg:pub.10.1007/bf00686141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011802558
186 https://doi.org/10.1007/bf00686141
187 rdf:type schema:CreativeWork
188 sg:pub.10.1007/s00415-019-09577-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121856716
189 https://doi.org/10.1007/s00415-019-09577-6
190 rdf:type schema:CreativeWork
191 sg:pub.10.1007/s10072-014-1709-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017883418
192 https://doi.org/10.1007/s10072-014-1709-5
193 rdf:type schema:CreativeWork
194 sg:pub.10.1007/s10072-019-03791-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1112519703
195 https://doi.org/10.1007/s10072-019-03791-w
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/s10072-019-03847-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1112941757
198 https://doi.org/10.1007/s10072-019-03847-x
199 rdf:type schema:CreativeWork
200 sg:pub.10.1038/ncpneuro0356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030282682
201 https://doi.org/10.1038/ncpneuro0356
202 rdf:type schema:CreativeWork
203 sg:pub.10.1038/s41582-018-0020-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104991494
204 https://doi.org/10.1038/s41582-018-0020-0
205 rdf:type schema:CreativeWork
206 grid-institutes:grid.11835.3e schema:alternateName Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK
207 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
208 schema:name Academic Department of Neurosciences, Royal Hallamshire Hospital and University of Sheffield, Sheffield, UK
209 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
210 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...